201. Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus.
- Author
-
Saito M, Kaibara A, Kadokura T, Toyoshima J, Yoshida S, Kazuta K, and Ueyama E
- Subjects
- Administration, Oral, Aged, Area Under Curve, Blood Glucose analysis, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 metabolism, Dose-Response Relationship, Drug, Female, Glomerular Filtration Rate physiology, Glucosides therapeutic use, Healthy Volunteers, Humans, Kidney metabolism, Kidney physiopathology, Male, Middle Aged, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Thiophenes therapeutic use, Blood Glucose metabolism, Diabetes Mellitus, Type 2 drug therapy, Glucosides pharmacology, Models, Biological, Renal Elimination drug effects, Sodium-Glucose Transporter 2 Inhibitors pharmacology, Thiophenes pharmacology
- Abstract
Aims: To provide a model-based prediction of individual urinary glucose excretion (UGE) effect of ipragliflozin, we constructed a pharmacokinetic/pharmacodynamic (PK/PD) model and a population PK model using pooled data of clinical studies., Methods: A PK/PD model for the change from baseline in UGE for 24 hours (ΔUGE
24h ) with area under the concentration-time curve from time of dosing to 24 h after administration (AUC24h ) of ipragliflozin was described by a maximum effect model. A population PK model was also constructed using rich PK sampling data obtained from 2 clinical pharmacology studies and sparse data from 4 late-phase studies by the NONMEM $PRIOR subroutine. Finally, we simulated how the PK/PD of ipragliflozin changes in response to dose regime as well as patients' renal function using the developed model., Results: The estimated individual maximum effect were dependent on fasting plasma glucose and renal function, except in patients who had significant UGE before treatment. The PK of ipragliflozin in type 2 diabetes mellitus (T2DM) patients was accurately described by a 2-compartment model with first order absorption. The population mean oral clearance was 9.47 L/h and was increased in patients with higher glomerular filtration rates and body surface area. Simulation suggested that medians (95% prediction intervals) of AUC24h and ΔUGE24h were 5417 (3229-8775) ng·h/mL and 85 (51-145) g, respectively. The simulation also suggested a 1.17-fold increase in AUC24h of ipragliflozin and a 0.76-fold in ΔUGE24h in T2DM patients with moderate renal impairment compared to those with normal renal function., Conclusions: The developed models described the clinical data well, and the simulation suggested mechanism-based weaker antidiabetic effect in T2DM patients with renal impairment., (© 2019 Astellas Pharma Inc. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.)- Published
- 2019
- Full Text
- View/download PDF